Sharemaestro Newsreel

Alpha Cognition Inc. Q2 2026: Revenue $6.09M, EPS $(0.40) — 10-Q Summary

Alpha Cognition Inc. (ACOG) reported its Q2 2026 results, showing revenues of $6.09 million, a significant increase year-over-year due to product sales from the newly launched ZUNVEYL. Despite higher product sales, the company posted a net loss of $8.79 million, although this was an …

NovaBridge webcast to cover oncology and ophthalmology programs

NovaBridge Biosciences (Nasdaq: NBP) announced it will host a webcast on Thursday, August 20, 2026, at 9:00 AM ET / 9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026. The company is …

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

NovaBridge Biosciences announced it will hold a webcast on Thursday, August 20, 2026, to discuss its first half 2026 financial results and corporate progress. The company, a global biotechnology firm focused on oncology and ophthalmology, will host the webcast at 9:00 AM ET/9:00 PM …

Satellos Q2 loss widens to $11.7M, EPS misses estimates

Satellos Bioscience reported a Q2 2026 net loss of $11.7 million, or $0.56 per share, missing analyst estimates due to significantly increased R&D spending on its Phase 2 DMD clinical trials. Despite the widening loss, the company's cash reserves rose to $61.8 million, providing …

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc. announced its Q2 2026 financial results, reporting a strong cash position of $61.8 million and progress in its clinical trials for SAT-3247, a drug candidate for Duchenne muscular dystrophy (DMD). The company highlighted favorable safety data from the TRAILHEAD adult DMD …

Satellos reports stable strength in four-adult Duchenne study

Satellos reported its second quarter 2026 financial results, including a net loss of $11.7 million, and provided updates on its clinical progress for SAT-3247 in Duchenne muscular dystrophy (DMD). The company highlighted stable strength and reduced muscle fat in a Phase 2 adult DMD …

Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash

Satellos Bioscience reported increased net losses in the first half of 2026 due to higher R&D and G&A expenses, driven by advancing its Duchenne muscular dystrophy (DMD) clinical programs, SAT-3247. Despite widening losses, the company significantly strengthened its cash position to $61.8 million through …

Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary

Estrella Immunopharma, Inc. reported a net loss of $(2.31M) for the second quarter of 2026, with a loss per share of $(0.05). The company remains pre-revenue, driven by ongoing development and corporate expenses. Key highlights include progress in clinical trials, significant milestones in a …

MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary

MapLight Therapeutics (MPLT) reported a net loss of $60.2 million and a loss per share of $(1.32) for the second quarter of 2026, remaining pre-revenue. The increased loss compared to Q2 2025 was due to a significant ramp in clinical trial activity and operational …

Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI) reported a quarterly loss of $0.07 per share, exceeding analyst estimates by $0.01. Despite beating expectations, shares fell 2.2% to $1.34. The company has an average "Hold" rating from analysts with a target price of $3.75, and director Gregg Williams recently …

Korro Bio director Jean Francois Formela sells $29,916 in shares

Korro Bio director Jean Francois Formela sold 2,143 shares of the company's common stock for approximately $29,916 on August 11, 2026, under a Rule 10b5-1 trading plan. Despite recent volatility and a 67% year-to-date return, InvestingPro analysis suggests the stock may be overvalued. The …

Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan

Korro Bio director Jean Francois Formela's affiliated funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 2,143 shares of Korro Bio common stock on August 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan …

DYN (DYN) insider notice details planned share sale and prior trades

A recent SEC Form 144 filing indicates a planned sale of 1,797 common shares of Dyne Therapeutics (DYN) valued at $47,226.00, scheduled for August 13, 2026, on Nasdaq. These shares are part of equity compensation, including 4,062 restricted stock units from August 12, 2026. …

Dyne Therapeutics, Inc. SEC Filing (Aug 13, 2026)

Dyne Therapeutics, Inc. (DYN) filed a Form 144 SEC document on August 13, 2026, indicating a proposed sale of securities. The filing details information about the issuer, the filer, and the securities to be sold, including 94,415 shares of common stock acquired via private …

Assembly Biosciences (NASDAQ:ASMB) Issues Quarterly Earnings Results, Beats Expectations By $0.52 EPS

Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings, beating analyst expectations with an adjusted loss of $0.20 per share, $0.52 better than forecast, and revenue of $13.37 million, exceeding estimates of $8.60 million. Following the news, shares rose significantly by $2.89 to $29.95 on high trading …

Kodiak Sciences misses Q2 estimates, shares fall 5%

Kodiak Sciences Inc. reported a wider net loss of -$1.05 per share in Q2, missing analyst estimates of -$0.98 per share, causing shares to drop over 5% in after-hours trading. The company's R&D expenses increased due to late-stage clinical programs for retinal diseases, though …

Celcuity beats second quarter loss estimates

Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …

Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway

Instil Bio (Nasdaq: TIL) reported a significantly trimmed net loss of $4.3 million in Q2 2026, down from $21.4 million in Q2 2025, driven by reduced operating expenses. The company also announced a strong cash position of $69.9 million, which is expected to fund …

Instil Bio, Inc. 2026: Revenue ($4.35M), Net income ($4.3M), EPS ($0.63) — 10-Q Summary

Instil Bio, Inc. reported its 2026 quarterly results, showing a significantly narrower net loss and reduced comprehensive loss compared to the previous year. This improvement is attributed to the company winding down development of its lead candidate, AXN-2510, and substantially cutting R&D activity and …

Form 8K Instil Bio Inc For: 13 August By Investing.com

This article reports on the filing of Form 8K by Instil Bio Inc. on August 13th, as tracked by Investing.com. The content itself is very brief, serving primarily as an announcement of the filing rather than providing detailed information about the filing's contents. It …

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio, Inc. (Nasdaq: TIL) reported its second quarter 2026 financial results, highlighting a cash position of approximately $69.9 million as of June 30, 2026, which is expected to fund operations beyond 2027. The biotechnology company is also actively evaluating potential acquisitions, in-licensing, and …

Instil Bio (TIL) slashes R&D spend and leans on Tarzana lease income in Q2 2026

Instil Bio (TIL) significantly reduced operating expenses and narrowed its net loss in Q2 2026 due to the discontinuation of certain R&D programs and restructuring efforts. The company reported a net loss of $4.3 million for the quarter and $8.5 million for the first …

CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates

CAMP4 Therapeutics reported a Q2 net loss of $33.5 million, significantly wider than the previous year, primarily due to a $20.9 million non-cash derivative loss, causing EPS of $(0.58) to miss estimates. Despite missing revenue consensus, the company's revenue rose 18.8% year-over-year. Post-quarter, CAMP4 …

Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS

Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss …

Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A

Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have reported a beneficial ownership of 16,244,339 shares, or 5.1%, of Taysha Gene Therapies, Inc. common stock as of June 30, 2026. This disclosure was made in an Amendment No. 2 to Schedule 13G …

CGON (CGON) investor lists 25,989-share sale after series of stock disposals

An investor in CG Oncology, Inc. (CGON) has filed a Form 144, indicating a planned sale of 25,989 common shares with an aggregate market value of $1,973,970.86, expected on August 13, 2026. This filing also discloses a series of prior open-market sales by Ambaw …

Capricor: Q2 Earnings Snapshot

This article provides a brief "Q2 Earnings Snapshot" for Capricor. The full content of the article is not available beyond the title, indicating it may be a placeholder or an article with minimal information.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Hagens Berman is encouraging investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to come forward regarding a securities fraud class action lawsuit. The lawsuit alleges that Capricor made false and misleading statements about the clinical trial data and regulatory pathway for …

Earnings call transcript: Capricor Therapeutics Q2 2026 loss narrows focus to FDA path

Capricor Therapeutics reported a wider-than-expected Q2 2026 loss of $0.70 per share but saw its stock surge 83.6% after hours due to positive investor focus on its updated regulatory strategy for deramiocel, its Duchenne muscular dystrophy treatment. The company announced the FDA is open …

Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ligand Pharmaceuticals (LGND) is back in focus after its recent second quarter report and reaffirmed 2026 guidance. The company posted US$63.69 million in quarterly revenue and US$48.51 …

MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal

Edesa Biotech Q3 Results: EPS misses estimate, losses widen 140% YoY

Ensysce Q2 Results: EPS beats estimate, sales up 16% vs view

Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85%

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences, Inc. (CRBU) reported a Q2 loss of $0.24 per share, outperforming the Zacks Consensus Estimate of a $0.33 loss. However, the company missed revenue estimates, posting $1.5 million against an expected $2.5 million. The stock currently holds a Zacks Rank #3 (Hold), …